A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Exclusion Criteria

• •1. Primary central nervous system (CNS) lymphoma; However, secondary CNS lymphoma without clinical symptoms can be enrolled after being determined by the researchers；
• •2. Use of the prescribed drugs or treatments within the specified time before the collection of PBMC;
• •3. Prior allogeneic hematopoietic stem cell transplantation;
• •4. Systemic intravenous infusion treatment or uncontrollable bacterial, fungal or viral infection within 2 weeks before signing the ICF;
• •5. A history of deep vein thrombosis or pulmonary embolism or anticoagulant therapy within 6 months before signing the ICF;
• •6. A clinically significant history of severe heart disease within 6 months before signing the ICF;
• •7. Terminal organ damage or autoimmune diseases requiring systemic immunosuppressive/systemic treatments within 2 years before signing the ICF; Or have graft-versus-host disease;
• •8. Prescribed malignant tumors within 5 years before signing the ICF;
• •9. Intestinal obstruction caused by tumor compression or vascular compression requiring emergency treatment; gastrointestinal involvement with a risk of bleeding assessed by the researchers;
• •10. Clinically significant CNS diseases in the past or at the time of screening;
• •11. A history of severe allergic reactions to the drugs or excipients that were definitely needed in this study. Or have a history of allergic reactions to tocilizumab;
• •12. Any indwelling tubes or drainage tubes in the bodies, the use of dedicated central venous access catheters is permitted;
• •13. Pregnant or breastfeeding women; or male or female subjects who are unwilling to use contraception from the time of signing the ICF until 1 year after receiving B019 injection cell infusion or until CAR is detectable in peripheral blood.;
• •14. The subjects who have participated in other clinical studies within the past 1 month, or whose last medication use for the last clinical study is still within the 5 half-life periods of the current drug at the time of screening;
• •15. Other circumstances that the researchers consider unsuitable for participating in this study.